

Supplemental Figure 6: *Generation FRα-targeted FR-B BiTE for use in preclinical mouse models and therapeutic testing of FR-B T cells:* **A)** Graphical depiction of FR-B retroviral construct configuration **B)** Specific binding of FR-B to IE9-mp1-hFRa cells and mouse CD8+ T cells. FR-Bh (which lacks mouse CD3 binding), Control Supernatant (Cont Sup) containing no BiTEs, and CD19+ B cells were included as staining controls. **C)** Experimental Design (left), tumor growth (middle), and survival of Pan02-hFRa tumor bearing mice treated locoregionally with 3 x 10^6 FR-B T cells or Unarmed Control T cells (2 doses) by SQ injection (n=6/group). *D)* Mice were lymphodepleted by delivery of 5Gy TBI immediately prior to IE9-mp1-hFRa tumor implantation, with delivery of 2.4 x 10^6 FR-B or Unarmed T cells 5 days later. Tumor progression was tracked based on accumulation of peritoneal ascites, measured as increased abdominal circumference (n=4-5/group). E) Representative FACs plots demonstrating limited persistence of FR-B CD8+ or CD4+ T cells in either the tumor or ascites at disease endpoint. Data presented as mean ± SEM. Data in C) is from one experiment and data in D) is from one representative experiment (two independent studies). C) Two-way ANOVA (left) and Log-rank Test (right), D) Two-way ANOVA, **** p<0.0001